This study is the first to combine a PD-L1 inhibitor and CTLA4 inhibitor to prolong the survival of patients with pMMR/MSS advanced refractory CRC, raising new hopes for immunotherapy for pMMR/MSS mCRC. The gene discussed is CD274; the disease is colorectal carcinoma.